Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION study of obinutuzumab in primary membranous nephropathy after rituximab intolerance, resistance, or dependence
2021-004864-81Phase 2Active
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of obinutuzumab in idiopathic membranous glomerulonephritis (IMG) (2 cohorts), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Incidence of complete or partial remission of nephrotic syndrome. Started Sep 2021; status: active.
02
Drugs
obinutuzumab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on 2021-004864-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004864-81.